Apricus Biosciences Presents Vitaros(R) Poster at the International Symposium on Prostate, Androgens and Men's Sexual Health

Apricus Biosciences Presents Vitaros(R) Poster at the International Symposium
on Prostate, Androgens and Men's Sexual Health

Data Demonstrate Increased Efficacy, Decreased Adverse Events, With Longer
Term Use

SAN DIEGO, June 21, 2013 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
("Apricus Bio" or the "Company") (Nasdaq:APRI) (www.apricusbio.com) announced
today that it will present a poster with results of an analysis of existing
Phase 3 data for Vitaros^®, the Company's lead product candidate for the
treatment of erectile dysfunction (ED), at the International Symposium on
Prostate, Androgens and Men's Sexual Health. The Symposium is being convened
jointly by the European Society of Sexual Medicine ("ESSM") and the
International Society for Sexual Medicine ("ISSM"), and is taking place June
21-23, 2013 in Berlin, Germany.

The poster, titled "Comparison of Vitaros^® Efficacy and Safety with
Short-term and Longer Term Use," (Poster #35) authored by John P. Mulhall,
M.D., Director of the Male Sexual and Reproductive Medicine Program at
Memorial Sloan-Kettering Cancer Center, is scheduled to be on display June
21-22, 2013 from 9:00 AM to 5:00 PM local time.

"Vitaros® addresses a large population of ED patients who cannot or do not
respond well to existing medications due to the systemic effects of PDE5
inhibitors, such as Viagra," said Rich Pascoe, Chief Executive Officer of
Apricus Bio. "With its innovative, on-demand topical administration, and rapid
onset in as little as five minutes, Vitaros^® can safely improve erectile
function in these patients with both short and longer term use."

This additional analysis of the Phase 3 data looked at the efficacy and safety
of Vitaros^® for short-term use (12 weeks; n=1,727) compared to longer-term
use (n=1,161). The results found that, following 12 weeks of treatment, a
statistically significant improvement in erectile function (EF) score was
observed for the Vitaros^® treatment group (1.6 for the 100 mcg dose group,
2.5 for the 200 mcg dose group, and 2.4 for the 300 mcg dose group) compared
to the placebo group (-0.7) (p<0.001). A significantly greater proportion of
patients receiving all dose levels of Vitaros^® (100 mcg, 200 mcg, 300 mcg)
reported improvement (up to 51%) in their erections compared to placebo. 

With longer-term exposure, nearly all of the subjects (100%, 100%, and 88.2%
in each of the 100mcg, 200mcg, and 300mcg dose groups respectively) had an
improvement in EF score, and greater than 90% of the patients reported
improvements in their erections. Compared to the end of the 12-week
treatment, the mean IIEF score continued to improve for men choosing the 300
mcg dose level. The increased efficacy and the longer term safety evaluated
in ED patients repeatedly exposed to Vitaros^® illustrated that efficacy does
not diminish with longer term use. 

The majority of adverse events (AEs) were transient, and mild or moderate in
intensity, and the incidence of AE reports decreased with repeated
exposure.Relative to 12-week Vitaros^® administration, longer term use of
Vitaros® resulted in consistent, dose-dependent overall improvement in EF and
fewer reports of transient urogenital adverse events.

The Company received approval effective May 31, 2013 of Vitaros^® in Europe as
a first line treatment for erectile dysfunction.The Company is currently
working independently, as well as with its commercialization partners, Sandoz,
Takeda, and Bracco, to obtain national phase approvals in France, Germany,
Italy, UK, Ireland, Spain, The Netherlands, Sweden, Belgium and Luxembourg in
order to make Vitaros^® ready to launch in each of these territories across
Europe.Vitaros^® is also approved in Canada.

About Vitaros^®

Vitaros^® is a topically-applied cream formulation of alprostadil, a
vasodilator, combined with our proprietary permeation enhancer DDAIP.HCL,
which directly increases blood flow to the penis, causing an
erection.Alprostadil is a widely accepted alternative to the PDE-5 inhibitors
for difficult to treat patients, and Vitaros^®, which was determined to be
safe and effective by the European Health Authorities and previously by Health
Canada, offers greater market opportunity due to its patient-friendly form
versus other alprostadil dosage forms and also relative to oral ED
products.With a market affecting nearly 150 million men worldwide and
representing approximately $1 billion in revenue in Europe, Vitaros^®
represents a major market opportunity, particularly as a distinct product that
addresses a significant underserved population.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and
markets innovative treatments that help large patient populations across
numerous, large-market therapeutic classes including male and female sexual
health.The Company has one approved product, Vitaros^®, for the treatment of
erectile dysfunction, which is now approved in Europe and Canada and will be
commercialized by Apricus Bio's marketing partners which include, Abbott
Canada, Takeda Pharmaceuticals International GmbH, Sandoz, and Bracco
SpA.Femprox^®, the Company's product candidate for the treatment of female
sexual arousal disorder, has successfully completed a nearly 400-subject
proof-of-concept study.

For further information on Apricus Bio, visit http://www.apricusbio.com.

Apricus Bio's Forward-Looking Statement Safe Harbor

Statements under the Private Securities Litigation Reform Act, as amended:
with the exception of the historical information contained in this release,
the matters described herein contain forward-looking statements that involve
risks and uncertainties that may individually or mutually impact the matters
herein described for a variety of reasons that are outside the control of the
Company, including, but not limited to, its ability to further develop its
product Vitaros^® for erectile dysfunction , and product candidate Femprox^®
for Female Sexual Arousal Disorder among others; to have its product and
product candidates receive additional patent protection and be approved by
relevant regulatory authorities in Europe, the United States and Canada and in
other countries; to successfully commercialize such product and product
candidates and other NexACT^® product candidates and drug delivery technology;
to sell its oncology supportive care business or assets to a third party or
parties; to cease funding to its French subsidiariesand to have such
subsidiaries reorganize or liquidate successfully; and to achieve its other
development, commercialization and financial goals. Readers are cautioned not
to place undue reliance on these forward-looking statements as actual results
could differ materially from the forward-looking statements contained herein.
Readers are urged to read the risk factors set forth in the Company's most
recent annual report on Form 10-K, subsequent quarterly reports filed on Form
10-Q and other filings made with the SEC. Copies of these reports are
available from the SEC's website or without charge from the Company.

CONTACT: Apricus Bio Investor Relations:
        
         David Pitts or Lourdes Catala
         Argot Partners
         212-600-1902
         david@argotpartners.com
         lourdes@argotpartners.com

Apricus logo
 
Press spacebar to pause and continue. Press esc to stop.